middle.news
Neurizon Advances NUZ-001 Amid FDA’s Targeted Data Request
9:14am on Monday 17th of February, 2025 AEDT
•
Biotechnology
Read Story
Neurizon Advances NUZ-001 Amid FDA’s Targeted Data Request
9:14am on Monday 17th of February, 2025 AEDT
Key Points
FDA requests additional animal exposure data for NUZ-001
No safety concerns identified from prior clinical studies
Neurizon confident in meeting FDA’s data requirements
Impact on ALS clinical trial timeline under assessment
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE